Bone marrow clues may explain leukemia relapse in 'good risk' patients
NCT ID NCT07379528
First seen Feb 01, 2026 · Last updated May 25, 2026 · Updated 16 times
Summary
This study looked at 70 adults with acute myeloid leukemia (AML) to understand why more than half of patients with favorable-risk genetics still relapse. Researchers focused on the bone marrow's support cells (mesenchymal stem cells) and how they might help leukemia stem cells survive chemotherapy. The goal was to find new markers that could predict which patients need more aggressive treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA (AML) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fondazione IRCCS Policlinico San Matteo
Pavia, Pavia, 27100, Italy
Conditions
Explore the condition pages connected to this study.